Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Change of Corporate Name and Reorganization of the Group StructureTimelineThe spacing between the points is proportional to the actual number of days.
Procedures and assumptions
Conditions Precedent to ExecutionApproval of the partial amendment to the Articles of Incorporation at the 22nd Annual General Meeting of Shareholders, scheduled for late June 2026
Management structure after acquisitionAs a holding company, the Company will oversee the 3 operating companies ADR セラピューティクス株式会社, ADR アニマルセラピー株式会社 (formerly 株式会社アニマルセラピー), and ADR バイオシステムズ株式会社 (formerly 株式会社 ADR genesis). The new corporate name will be ADR バイオメディカルホールディングス株式会社.
| Item | Details |
|---|---|
| Transaction name | Change of Corporate Name and Reorganization of the Group Structure |
| Date of board resolution | 27 April 2026 |
| Execution Date / Effective Date | 1 July 2026 (scheduled) |
| Conditions Precedent to Execution | Approval of the partial amendment to the Articles of Incorporation at the 22nd Annual General Meeting of Shareholders, scheduled for late June 2026 |
| Management structure after acquisition | As a holding company, the Company will oversee the 3 operating companies ADR セラピューティクス株式会社, ADR アニマルセラピー株式会社 (formerly 株式会社アニマルセラピー), and ADR バイオシステムズ株式会社 (formerly 株式会社 ADR genesis). The new corporate name will be ADR バイオメディカルホールディングス株式会社. |
Items this document does not state (27)
Counterparty nameName of the Subject CompanyBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceContract DateValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The changes are intended to expand the business and strengthen the earnings base by expanding the cell therapy business, transitioning to a manufacturing structure in Japan, expanding the medical device business centered on centrifuges, and reviewing product and service prices. The Company also states that it will clarify its two-pronged strategy centered on the “cell therapy” and “equipment and manufacturing” areas, thereby enhancing the specialization and growth potential of its businesses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.